Yes, you may carry the cream in its original packaging with a copy of the prescription. Declare it at security if asked, and keep it in your hand luggage to avoid temperature extremes.
Nizolar Cream 2% is supplied in a white, squeezable 15 g tube with a blue flip-top cap. The tube bears the brand name “Nizoral” and the dosage “2 %”. No specific imprint code is required for prescription creams.
Topical ketoconazole is not listed as a prohibited substance by the World Anti-Doping Agency (WADA). Routine drug tests focus on systemic agents, so the cream should not cause a positive result.
The MHRA approval is for patients 12 years and older. Use in infants is off-label and should only be considered after specialist advice.
It is best to apply Nizoral Cream alone and allow it to dry fully before using moisturisers or other topical agents, unless your clinician advises otherwise.
Typical dosing (thin film twice daily) uses approximately 0.5 g per application, so a 15 g tube generally lasts about 2 weeks, matching the recommended treatment course.
Ketoconazole crosses the placenta in very low amounts when used topically. It should be used only if the therapeutic benefit justifies any potential risk, after discussion with a healthcare professional.
Discontinue the cream immediately and seek medical advice. The reaction may be an allergic contact dermatitis requiring alternative treatment.
Yes, several UK pharmacies stock generic ketoconazole 2 % cream, which contains the same active ingredient and strength as Nizoral Cream but may be marketed under different brand names.
Do not flush the cream down the toilet. Return the tube to a local pharmacy’s medicine-return scheme or follow NHS guidelines for safe disposal of unwanted medicines.
Nizoral Cream 2% contains the active ingredient ketoconazole, an antifungal agent belonging to the azole class. It is supplied in a 15 g tube for topical use. In the United Kingdom, Nizoral Cream is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA).
The cream is formulated to treat superficial fungal infections of the skin by inhibiting the growth of susceptible fungi.
Ketoconazole interferes with the fungal cell membrane by blocking the enzyme lanosterol 14α-demethylase. This enzyme is essential for converting lanosterol into ergosterol, the primary sterol that maintains fungal cell membrane integrity. Without ergosterol, the membrane becomes permeable, leading to fungal cell death.
Key pharmacologic points for topical ketoconazole:
Nizoral Cream is approved by the MHRA for the following indications:
These conditions are caused by susceptible dermatophytes or yeasts such as Malassezia species.
Some clinicians use ketoconazole 2 % cream for other superficial fungal conditions when standard therapy fails, for example:
These uses are not approved by the MHRA. Off-label application should be decided by a qualified healthcare professional after weighing potential risks and benefits.
These reactions often resolve without intervention; applying a moisturiser after the cream dries may help.
Systemic absorption of ketoconazole from the cream is minimal, so significant drug-drug interactions are unlikely. However:
Routine laboratory monitoring is not required for short-term topical therapy. Patients should:
This article provides educational information about Nizoral Cream 2% and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
